ALLO

Allogene Therapeutics Inc (ALLO)

US
$ 1.36-4.9%

Price Chart

Key Statistics

Market Cap
$ 253.73M
P/E Ratio
0.00
Revenue (TTM)
$ 0
Volume
3.13M
52W High
$ 3.78
52W Low
$ 0.86
Dividend Yield
0.00%
Beta
0.60

Technicals

50-Day MA
1.4856
200-Day MA
2.1339
52 Week High
3.78
52 Week Low
0.8621

About ALLO

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.

Employees
226
Headquarters
South San Francisco, CA
CEO
Dr. Arie S. Belldegrun F.A.C.S., M.D.

Advanced Charts

Access professional-grade trading charts and technical analysis tools

Top Gainers

Symbol/Name
LTP
% Chg

Top Losers

Symbol/Name
LTP
% Chg